Publique en esta revista
Información de la revista
Vol. 49. Núm. S1.
Consenso SEPAR-ALAT sobre terapia inhalada
Páginas 2-14 (Enero 2013)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 49. Núm. S1.
Consenso SEPAR-ALAT sobre terapia inhalada
Páginas 2-14 (Enero 2013)
DOI: 10.1016/S0300-2896(13)70068-1
Acceso a texto completo
Consenso SEPAR-ALAT sobre terapia inhalada
SEPAR-ALAT Consensus for Inhaled Therapies
Visitas
...
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Giner, L.V. Basualdo, P. Casan, C. Hernández, V. Macian, I. Martínez, et al.
Normativa SEPAR para la utilización de fármacos inhalados. Recomendaciones SEPAR N.º 22.
Doyma, (1997),
[2.]
V. Giraud, N. Roche.
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability.
Eur Respir J, 19 (2002), pp. 246-251
[3.]
A.S. Melani, M. Bonavia, V. Cilenti, C. Cinti, M. Lodi, P. Martucci, et al.
Inhaler mishandling remains common in real life and is associated with reduced disease control.
Respir Med, 105 (2011), pp. 930-938
[4.]
V. Plaza, J. Sanchis, P. Roura, J. Molina, M. Calle, S. Quirce, et al.
Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain.
J Aerosol Med Pulm Drug Deliv, 25 (2012), pp. 16-22
[5.]
D. Price, S. Bosnic-Anticevich, A. Briggs, H. Chrystyn, C. Rand, G. Scheuch, The Inhaler Error Steering Committee, et al.
Inhaler competence in asthma: common errors, barriers to use and recommended solutions.
Respir Med, 107 (2013), pp. 37-46
[6.]
J. Sanchis, C. Corrigan, M.L. Levy, J.L. Viejo, ADMIT Group.
Inhaler devices–from theory to practice.
Respir Med, 107 (2013), pp. 495-502
[7.]
B.L. Laube, H.M. Janssens, F.H. De Jongh, S.G. Devadason, R. Dhand, P. Diot, European Respiratory Society; International Society for Aerosols in Medicine, et al.
What the pulmonary specialist should know about the new inhalation therapies.
Eur Respir J, 37 (2011), pp. 1308-1331
[8.]
V. Plaza, M. Calle, J. Molina, S. Quirce, J. Sanchis, J.L. Viejo, et al.
Validación externa de las recomendaciones del Consenso multidisciplinar sobre Terapia Inhalada.
Arch Bronconeumol, 48 (2012), pp. 189-196
[9.]
Inhalation aerosols. Physical and biological basis for therapy, 2nd,
[10.]
S.P. Newman.
Aerosol deposition considerations in inhalation therapy.
Chest, 882 (1985), pp. 152S-160S
[11.]
A. Fernández Tena, P. Casan Clarà.
Depósito pulmonar de partículas inhaladas.
Arch Bronconeumol, 48 (2012), pp. 240-246
[12.]
M. Lippmann, D.B. Yeates, R.E. Albert.
Deposition, retention, and clearance of inhaled particles.
Br J Ind Med, 37 (1980), pp. 337-362
[13.]
M.A. Dolovich.
Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung.
Respir Care, 45 (2000), pp. 597-608
[14.]
L. De Rochefort, L. Vial, R. Fodil, X. Maitre, B. Louis, D. Isabey, et al.
In vitro validation of computational fluid dynamic simulation in human proximal airways with hyperpolarized 3He magnetic resonance phase-contrast velocimetry.
J Appl Physiol, 102 (2007), pp. 2012-2023
[15.]
D.B. Gail, C.J. Lenfant.
Cells of the lung: biology and clinical implications.
Am Rev Respir Dis, 127 (1983), pp. 366-387
[16.]
P. Satir, M.A. Sleigh.
The physiology of cilia and mucociliary interactions.
Annu Rev Physiol, 52 (1990), pp. 137-155
[17.]
L. Hendeles, G.L. Colice, R.J. Meyer.
Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
N Engl J Med, 356 (2007), pp. 1344-1351
[18.]
M.B. Dolovich, R. Dhand.
Aerosol drug delivery: developments in device design and clinical use.
Lancet, 377 (2011), pp. 1032-1045
[19.]
N. Scichilone, M. Spatafora, S. Battaglia, R. Arrigo, A. Benfante, V. Bellia.
Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations.
J Asthma Allergy, 6 (2013), pp. 11-21
[20.]
B.J. Gabrio, S.W. Stein, D.J. Velasquez.
A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers.
Int J Pharm, 186 (1999), pp. 3-12
[21.]
S.P. Newman, A.W. Weisz, N. Talaee, S.W. Clarke.
Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique.
Thorax, 46 (1991), pp. 712-716
[22.]
B. Zierenberg, J. Eicher, S. Dunne, B. Freund.
Boehringer Ingelheim nebulizer BINEB®: a new approach to inhalation therapy.
Proceedings of Respiratory Drug Delivery V, pp. 187-193
[23.]
B. Zierenberg.
Optimizing the in vitro performance of Respimat.
J Aerosol Med, 12 (1999), pp. S19-S24
[24.]
F. Lavorini, G.A. Fontana.
Targeting drugs to the airways: The role of spacer devices.
Expert Opin Drug Deliv, 6 (2009), pp. 91-102
[25.]
J. Boe, J.H. Dennis, B.R. O’Driscoll, T.T. Bauer, M. Carone, B. Dautzenberg, European Respiratory Society Task Force on the use of nebulizers, et al.
European Respiratory Society Guidelines on the use of nebulizers.
Eur Respir J, 18 (2001), pp. 228-242
[26.]
J.C. Virchow, G.K. Crompton, R. Dal Negro, S. Pedersen, A. Magnan, J. Seidenberg, et al.
Importance of inhaler devices in the management of airway disease.
Respir Med, 102 (2008), pp. 10-19
[27.]
W. Wilkes, J. Fink, R. Dhand.
Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler.
J Aerosol Med, 14 (2001), pp. 351-360
[28.]
J. Panicker, G.R. Sethi, V. Sehgal.
Comparative efficiency of commercial and improvised spacer device in acute bronchial asthma.
Indian Pediatr, 38 (2001), pp. 340-348
[29.]
H.J. Zar, E.G. Weinberg, H.J. Binns, F. Gallie, M.D. Mann.
Lung deposition of aerosol–a comparison of different spacers.
Arch Dis Child, 82 (2000), pp. 495-498
[30.]
J. Giner, M. Torrejon, A. Ramos, P. Casan, C. Granel, V. Plaza, et al.
Preferencias de los pacientes en la elección de dispositivos de inhalación en polvo.
Arch Bronconeumol, 40 (2004), pp. 106-109
[31.]
A.R.H.A. Clark.
The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing.
J Aerosol Med, 6 (1993), pp. 99-110
[32.]
H. Chrystyn.
Effects of device design on patient compliance: comparing the same drug in different devices.
Respiratory Drug Delivery Europe 2009, pp. 105-116
[33.]
O.S. Usmani, M.F. Biddiscombe, P.J. Barnes.
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Am J Respir Crit Care Med, 172 (2005), pp. 1497-1504
[34.]
H. Chrystyn, D. Price.
What you need to know about inhalers and how to use them.
Prescriber, 20 (2009), pp. 47-52
[35.]
R. Sechaud, M. Sudershan, S. Perry, H. Hara, A. Drollmann, R. Karan, et al.
Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man.
ERS Annual Congress,
[36.]
P. Colthorpe, T. Voshaar, T. Kieckbusch, E. Cuoghi, J. Jauernig.
Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long acting muscarinic antagonist glycopyrronium.
Journal of Drug Assessment. 2013 Journal of Drug Assessment, 2 (2013), pp. 11-16
[37.]
G.M. Pover, C.G. Langdon, S.R. Jones, C. Fidler.
Evaluation of a breath operated powder inhaler.
J Int Med Res, 16 (1988), pp. 201-203
[38.]
H. Chrystyn.
The Diskus: a review of its position among dry powder inhaler devices.
Int J Clin Pract, 61 (2007), pp. 1022-1036
[39.]
K. Wetterlin.
Turbuhaler: a new powder inhaler for administration of drugs to the airways.
Pharm Res, 5 (1988), pp. 506-508
[40.]
H. Magnussen, H. Watz, I. Zimmermann, S. Macht, R. Greguletz, M. Falques, et al.
Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD.
Respir Med, 103 (2009), pp. 1832-1837
[41.]
S.P. Newman, D.J. Sutton, R. Segarra, R. Lamarca, G. De Miquel.
Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.
Respiration, 78 (2009), pp. 322-328
[42.]
H. Chrystyn.
Closer to an ‘ideal inhaler’ with the Easyhaler: an innovative dry powder inhaler.
Clin Drug Investig, 26 (2006), pp. 175-183
[43.]
T.T. Yang, S. Li, B. Wyka, D. Kenyon.
Drug delivery performance of the mometasone furoate dry powder inhaler.
J Aerosol Med, 14 (2001), pp. 487-494
[44.]
F. Mariotti, F. Sergio, D. Acerbi, T. Meyer, C. Herpich.
Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients.
ERS Annual Congress,
[45.]
D. Singh, G. Lucci, D. Acerbi, F. Sergio, I. Montagna, S. Vezzoli, et al.
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®.
ERS Annual Congress,
[46.]
P.G. Linnane, T. Voshaar, M. Spinola, A. Campanini, D. Lock, M. Scuri, et al.
Usability evaluation of NEXThaler® versus Diskus® and Turbuhaler®.
ERS Annual Congress,
[47.]
J. Lotvall, E.D. Bateman, E.R. Bleecker, W.W. Busse, A. Woodcock, R. Follows, et al.
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.
Eur Respir J, 40 (2012), pp. 570-579
[48.]
D.R. Hess.
Aerosol delivery devices in the treatment of asthma.
Respir Care, 53 (2008), pp. 699-723
[49.]
S. Newman, A. Gee-Turner.
The Omron MicroAir vibrating mesh nebulizer, a 21st century approach to inhalation.
J Appl Ther Res, 5 (2005), pp. 29-33
[50.]
J.C. Waldrep, A. Berlinski, R. Dhand.
Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.
J Aerosol Med, 20 (2007), pp. 310-319
[51.]
R. Dhand.
Aerosol delivery during mechanical ventilation: from basic techniques to new devices.
J Aerosol Med Pulm Drug Deliv, 21 (2008), pp. 45-60
[52.]
H.M. Janssens, H.A. Tiddens.
Aerosol therapy: the special needs of young children.
Paediatr Respir Rev, 7 (2006), pp. S83-S85
[53.]
F. Burgos.
¿Son compatibles la calidad y el uso extensivo de la espirometría?.
Arch Bronconeumol, 42 (2006), pp. 311-313
[54.]
M.B. Dolovich, R.C. Ahrens, D.R. Hess, P. Anderson, R. Dhand, J.L. Rau, et al.
Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology.
Chest, 127 (2005), pp. 335-371
[55.]
V. Plaza, J. Sanchis.
Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group.
Respiration, 65 (1998), pp. 195-198
[56.]
V. Plaza, J. Sanchis, P. Roura, J. Molina, M. Calle, S. Quirce, et al.
Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain.
J Aerosol Med Pulm Drug Deliv, 25 (2012), pp. 16-22
[57.]
J. Van der Palen, J.J. Klein, C.L. Van Herwaarden, G.A. Zielhuis, E.R. Seydel.
Multiple inhalers confuse asthma patients.
Eur Respir J, 14 (1999), pp. 1034-1037
[58.]
S.W. Stoloff, D.A. Stempel, J. Meyer, R.H. Stanford, J.R. Carranza Rosenzweig.
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
J Allergy Clin Immunol, 113 (2004), pp. 245-251
[59.]
J.B. Fink, B.K. Rubin.
Problems with inhaler use: a call for improved clinician and patient education.
Respir Care, 50 (2005), pp. 1360-1374
[60.]
J.L. Rau.
Practical problems with aerosol therapy in COPD.
Respir Care, 51 (2006), pp. 158-172
[61.]
Gema educadores. Manual del educador en asma. Madrid: Editorial Luzán 5; 2010. Disponible en: http://www.gemasma.com
[62.]
A. López Viña.
Actitudes para fomentar el cumplimiento terapéutico en el asma.
Arch Bronconeumol, 41 (2005), pp. 334-340
[63.]
M.E. Hyland.
Types of noncompliance.
Eur Respir Rev, 8 (1998), pp. 255-259
[64.]
S.P. Newman, F. Morén, D. Pavia, F. Little, S.W. Clarke.
Deposition of pressurized suspension aerosols inhaled through extension devices.
Am Rev Respir Dis, 124 (1981), pp. 317-320
[65.]
W. De Backer, A. Devolder, G. Poli, D. Acerbi, R. Monno, C. Herpich, et al.
Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
J Aerosol Med Pulm Drug Deliv, 23 (2010), pp. 137-148
[66.]
S.P. Newman, G.R. Pitcairn, D.A. Adkin, M.T. Vidgren, M. Silvasti.
Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer.
J Aerosol Med, 14 (2001), pp. 217-225
[67.]
J. Richards, P. Hirst, G. Pitcairn, S. Mahashabde, W. Abramowitz, A. Nolting, et al.
Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants.
J Aerosol Med, 14 (2001), pp. 197-208
[68.]
S.P. Newman, J. Brown, K.P. Steed, S.J. Reader, H. Kladders.
Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices.
Chest, 113 (1998), pp. 957-963
[69.]
H.M. Janssens, A. Krijgsman, T.F. Verbraak, W.C. Hop, J.C. De Jongste, H.A. Tiddens.
Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model.
J Aerosol Med, 17 (2004), pp. 51-61
[70.]
C. Leach.
Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans.
J Allergy Clin Immunol, 104 (1999), pp. S250-S252
[71.]
C.L. Leach, P.J. Davidson, R.J. Boudreau.
Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.
Eur Respir J, 12 (1998), pp. 1346-1353
[72.]
S. Häussermann, D. Acerbi, P. Brand, C. Herpich, G. Poli, K. Sommerer, et al.
Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients.
J Aerosol Med, 20 (2007), pp. 331-341
[73.]
R. Nave.
Determination of lungdeposition following inhalation of ciclesonide using different bioanalytical procedures.
Bioanalysis, 2 (2010), pp. 807-814
[74.]
S. Newman, A. Salmon, R. Nave, A. Drollmann.
High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.
Respir Med, 100 (2006), pp. 375-384
[75.]
S.P. Newman, M.T. Newhouse.
Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects.
J Aerosol Med, 9 (1996), pp. 55-57
[76.]
P. Brand, B. Hederer, G. Austen, H. Dewberry, T. Meyer.
Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
Int J Chron Obstruct Pulmon Dis, 3 (2008), pp. 763-770
[77.]
G. Pitcairn, S. Reader, D. Pavia, S. Newman.
Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
J Aerosol Med, 18 (2005), pp. 264-272
[78.]
L. Agertoft, S. Pedersen.
Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.
Am J Respir Crit Care Med, 168 (2003), pp. 779-782
[79.]
T. Meyer, P. Brand, H. Ehlich, R. Köbrich, G. Meyer, F. Riedinger, et al.
Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data.
J Aerosol Med, 17 (2004), pp. 43-49
[80.]
R. Delvadia, M. Hindle, P.W. Longest, P.R. Byron.
In Vitro Tests for Aerosol Deposition II: IVIVCs for Different Dry Powder Inhalers in Normal Adults.
J Aerosol Med Pulm Drug Deliv, (2012),
[81.]
P.H. Hirst, R.E. Bacon, G.R. Pitcairn, M. Silvasti, S.P. Newman.
A comparison of the lung deposition of budesonide from Easyhaler. Turbuhaler and pMDI plus spacer in asthmatic patients.
Respir Med, 95 (2001), pp. 720-727
[82.]
M. Vidgren, A. Kärkkäinen, P. Karjalainen, P. Paronen, J. Nuutinen.
Effect of powder inhaler design on drug deposition in the respiratory tract.
Int J Pharm, 42 (1988), pp. 211-216
[83.]
S.P. Newman, F. Morén, E. Trofast, N. Talaee, S.W. Clarke.
Deposition and clinical efficacy of terbutalinesulphate from Turbuhaler, a new multi-dose powder inhaler.
Eur Respir J, 2 (1989), pp. 247-252
[84.]
L. Thorsson, S. Edsbäcker, T.B. Conradson.
Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.
Eur Respir J, 7 (1994), pp. 1839-1844
[85.]
L. Borgström, E. Bondesson, F. Morén, E. Trofast, S.P. Newman.
Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.
Eur Respir J, 7 (1994), pp. 69-73
[86.]
Y. Zhang, K. Gilbertson, W.H. Finlay.
In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
J Aerosol Med, 20 (2007), pp. 227-235
[87.]
R. Berger, W.E. Berger.
Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler.
Allergy Asthma Proc, 34 (2013), pp. 52-58
[88.]
Becker A, Lemanske R, Pedersen S, Sly PL, Soto-Quiroz M, Wong GW, et al. Global Strategy for Asthma Management and Prevention in Children 5 Years and Younger. 2009. Disponible en: http://www.ginasthma.org
[89.]
M.L. García García.
Inhaladores para el lactante y el niño.
pp. 107-114
Copyright © 2013. Sociedad Española de Neumología y Cirugía Torácica
Idiomas
Archivos de Bronconeumología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?